• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cardiol Therapeutics (NQ: CRDL )

    2.040 +0.050 (+2.51%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 89,398
    Open 2.020
    Bid (Size) 1.970 (1)
    Ask (Size) 2.040 (1)
    Prev. Close 1.990
    Today's Range 1.990 - 2.090
    52wk Range 0.6610 - 3.120
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
    CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
    In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
    Via TheNewswire.com
    Exposures Product Safety

    Performance

    YTD
    +131.82%
    +131.82%
    1 Month
    -7.27%
    -7.27%
    3 Month
    -13.56%
    -13.56%
    6 Month
    +37.84%
    +37.84%
    1 Year
    +120.78%
    +120.78%

    More News

    Read More
    Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
    Via News Direct
    Exposures Product Safety
    Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
    Via Newsfile
    Sector Spotlight: Orphan Drug Developers With Significant Upside
    Via AB Newswire
    Topics ETFs
    Exposures Product Safety
    Stocks That Hit 52-Week Lows On Wednesday
    Via Benzinga
    Sector Spotlight: Orphan Drug Developers With Significant Upside
    Via TheNewswire.com
    Topics ETFs
    Exposures Product Safety
    Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
    Via AB Newswire
    Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
    Via News Direct
    CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
    Via InvestorPlace
    Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
    Via Newsfile
    Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
    Via Newsfile
    Exposures Product Safety
    Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite
    Via Talk Markets
    Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
    Via Newsfile
    Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
    Via Get News
    Topics Death
    Exposures Death
    Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
    Via News Direct
    Topics Death
    Exposures Death
    Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
    Via TheNewswire.com
    Topics Death
    Exposures Death
    Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations
    Via Benzinga
    CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
    Via Benzinga
    Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
    Via Newsfile
    Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
    Via Newsfile
    Sidoti's Micro-Cap Virtual May Conference
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.